Sonidegib (Odomzo) for Basal Cell Carcinoma - Details


( Last Updated : April 29, 2021)
Generic Name:
Sonidegib
Project Status:
Complete
Therapeutic Area:
Basal Cell Carcinoma
Manufacturer:
Sun Pharma Canada Inc.
Brand Name:
Odomzo
Project Line:
Reimbursement Review
Project Number:
PC0215-000
NOC Date:

Details


Strength:
200 mg
Tumour Type:
Skin and Melanoma
Indications:
Basal Cell Carcinoma (BCC)
Funding Request:
For the treatment of adult patients with histologically confirmed locally advanced basal cell carcinoma (laBCC) that is not amenable to radiation therapy or curative surgery.
Review Status:
Notification to Implement Issued
Sponsor:
Sun Pharma Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.